|
NCT04542213
|
Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19 |
Completed |
Phase 3 |
Aug/01/2020 |
Feb/28/2021 |
- Alternative id - CEI-22-2020
- Interventions - Drug: Linagliptin tablet|Drug: Insulin
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Regional de Alta Especialidad del Bajìo, Leòn, Guanajuato, Mexico
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 70
- Age - 18 Years to 75 Years (Adult, Older Adult)
- Outcome measures - Glucose levels|Number of patients who achieve metabolic control|Number of patients who die or need mechanical ventilation|C reactive protein levels
|
|
NCT04341935
|
Effects of DPP4 Inhibition on COVID-19 |
Withdrawn |
Phase 4 |
Jun/30/2021 |
Dec/30/2021 |
- Alternative id - 20200384
- Interventions - Drug: Linagliptin|Drug: Insulin regimen
- Study type - Interventional
- Study results - No Results Available
- Locations - University of Miami, Miami, Florida, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 0
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Changes in Glucose Llevels|Changes in SpO2 levels|Changes in Interleukin 6 (IL6)|Changes in chest structures
|
|
NCT04365127
|
Progesterone for the Treatment of COVID-19 in Hospitalized Men |
Completed |
Phase 1 |
Apr/27/2020 |
Aug/20/2020 |
- Alternative id - STUDY00000611
- Interventions - Drug: Progesterone 100 MG
- Study type - Interventional
- Study results - No Results Available
- Locations - Cedars Sinai Medical Center, Los Angeles, California, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 40
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Change in clinical status of subjects at Day 7 based on the following 7-point ordinal scale|Change in clinical status of subjects assessed daily while hospitalized and on Day 15|Duration of supplemental oxygen, mechanical ventilation (if applicable), and hospitalization
|
|
NCT04865029
|
Estradiol and Progesterone in Hospitalized COVID-19 Patients |
Recruiting |
Phase 2 |
Jul/22/2021 |
May/01/2022 |
- Alternative id - 2020-939
- Interventions - Other: Placebo injection and placebo pill|Drug: Estradiol Cypionate 5 MG/ML|Drug: Progesterone 200 MG Oral Capsule
- Study type - Interventional
- Study results - No Results Available
- Locations - Tulane University Medical Center, New Orleans, Louisiana, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 120
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - The proportion of patients who achieve scores 1 or 2 on the 9-point World Health Organization (WHO) ordinal scale through day 28.|Length of hospital stay|Readmission|Duration of mechanical ventilation|Time of death|Cause of death|Change in biological markers ferritin, procalcitonin and troponin|Change in biological markers C-reactive protein and D-Dimer|Change in hypercoagulability marker fibrinogen|Change in tissue injury markers ALT, AST and LDH|Change in inflammation marker neutrophil:lymphocyte ratio|Grade 3 and 4 adverse events occurrence|Serious adverse events occurrence
|
|
NCT03262051
|
Impact of Acute and Chronic Inflammation on Cytochromes P450 Activity Measured With Dried Blood Spot |
Recruiting |
|
Sep/01/2017 |
Sep/01/2021 |
- Alternative id - 2016-02232
- Interventions - Diagnostic Test: CYP phenotyping
- Study type - Observational
- Study results - No Results Available
- Locations - Geneva University Hospitals, HUG, Genève, Switzerland
- Study designs - Observational Model: Cohort|Time Perspective: Prospective
- Enrollment - 106
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Evaluate the impact of IL6 levels on the activity of CYPs in patients with acute (post orthopaedic surgery -hip or post SARS-CoV-2 infection) and chronic (rheumatoid arthritis) inflammation.|Evaluate the correlation between the activity of CYPs and CRP levels|Evaluate the correlation between the activity of CYPs and TNF-α levels|Evaluate the correlation between the activity of CYPs and IL-1β levels|Evaluate the correlation between the activity of CYPs and IFN-γ levels|Assess if tocilizumab reverse the activity of CYP in patients with RA after 3 months of treatment|Assess if SARS-CoV-2 infection modify pharmacokinetic parameters of concomitant medications which are CYPs substrates|Evaluate the correlation between inflammatory markers, CYP function and intensity of fatigue (MFI) and pain (NRS)
|
